Nourianz
Drug
Kyowa Kirin, Inc.
Total Payments
$3.0M
Transactions
14,372
Doctors
3,958
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $837,650 | 6,089 | 2,386 |
| 2023 | $1.6M | 6,066 | 2,292 |
| 2022 | $576,258 | 2,217 | 1,355 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.3M | 430 | 42.4% |
| Unspecified | $831,491 | 25 | 27.6% |
| Consulting Fee | $329,842 | 103 | 10.9% |
| Food and Beverage | $300,949 | 13,064 | 10.0% |
| Travel and Lodging | $146,019 | 704 | 4.8% |
| Space rental or facility fees (teaching hospital only) | $117,520 | 45 | 3.9% |
| Grant | $10,000 | 1 | 0.3% |
Payments by Type
General
$2.2M
14,347 transactions
Research
$831,491
25 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Istradefylline effect on Parkinsons Disease Tremor, Motor symptoms and Non-motor symptoms | Kyowa Kirin, Inc. | $274,391 | 0 |
| Istradefylline for Parkinson disease dementia | Kyowa Kirin, Inc. | $244,393 | 0 |
| A Phase 2 Study for Screening and Prevention of Adult T-cell Leukemia/Lymphoma with Mogamulizumab in High-Risk Carriers of HTLV-1 | Kyowa Kirin, Inc. | $156,023 | 0 |
| Development of new lymph node response criteria by using novel radiological quantitative techniques. | Kyowa Kirin, Inc. | $75,000 | 0 |
| Effectiveness of Istradefylline on Motor Functions in Patients with Parkinson's Disease | Kyowa Kirin, Inc. | $49,069 | 0 |
| An open label study to evaluate the safety and efficacy of combination extracorporeal photopheresis (ECP) and mogamulizumab in erythrodermic CTCL | Kyowa Kirin, Inc. | $32,615 | 0 |
Top Doctors Receiving Payments for Nourianz
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Ramon Lugo | — | Coral Gables, FL | $949,387 | 80 |
| , DO | Neurology | Philadelphia, PA | $145,267 | 135 |
| , MD | Neurology | Oklahoma City, OK | $117,684 | 143 |
| , MD | Neurology | Boca Raton, FL | $113,819 | 59 |
| , M.D | Neurology | Alexandria, VA | $112,613 | 134 |
| , MD | Neurology | Georgetown, TX | $89,035 | 169 |
| , M.D | Neurology | Herrin, IL | $78,578 | 90 |
| , MD, PH.D | Neurology | New York, NY | $64,664 | 85 |
| , M.D | Neurology | Dallas, TX | $62,372 | 144 |
| , M.D | Neurology | Loma Linda, CA | $61,124 | 42 |
| , D.O, | Neurology | Washington, DC | $59,671 | 90 |
| , M.D | Neurology | Hawthorne, NY | $57,143 | 43 |
| , M.D | Neurology | Commack, NY | $56,348 | 52 |
| , M.D | Neurology | Theodore, AL | $50,797 | 54 |
| , MD | Neurology | Augusta, GA | $45,250 | 27 |
| , M.D | Neurology | Washington, DC | $40,593 | 45 |
| , M.D., J.D | Neurology | Philadelphia, PA | $40,078 | 27 |
| , MD | Neurology | Tampa, FL | $39,231 | 34 |
| , MD | Neurology | Phoenix, AZ | $36,140 | 50 |
| , MD | Neurology | Cincinnati, OH | $32,869 | 34 |
| , M.D | Neurology | Staten Island, NY | $32,652 | 65 |
| , M.D | Neurology | Kansas City, KS | $31,832 | 27 |
| , D.O | Neurology | Newport Beach, CA | $30,285 | 49 |
| , MD | Neurology | Richmond, VA | $28,721 | 15 |
| , MD | Neurology | Houston, TX | $25,950 | 39 |
Ad
Manufacturing Companies
- Kyowa Kirin, Inc. $3.0M
- Kyowa Kirin Co., Ltd $10,755
Product Information
- Type Drug
- Total Payments $3.0M
- Total Doctors 3,958
- Transactions 14,372
About Nourianz
Nourianz is a drug associated with $3.0M in payments to 3,958 healthcare providers, recorded across 14,372 transactions in the CMS Open Payments database. The primary manufacturer is Kyowa Kirin, Inc..
Payment data is available from 2022 to 2024. In 2024, $837,650 was paid across 6,089 transactions to 2,386 doctors.
The most common payment nature for Nourianz is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.3M, 42.4% of total).
Nourianz is associated with 6 research studies, including "Istradefylline effect on Parkinsons Disease Tremor, Motor symptoms and Non-motor symptoms" ($274,391).